{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fregonese F"],"funding":["World Health Organization","Intramural CDC HHS","CIHR"],"pagination":["265-275"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9017096"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(4)"],"pubmed_abstract":["<h4>Background</h4>Isoniazid-resistant, rifampicin-susceptible (INH-R) tuberculosis is the most common form of drug resistance, and is associated with failure, relapse, and acquired rifampicin resistance if treated with first-line anti-tuberculosis drugs. The aim of the study was to compare success, mortality, and acquired rifampicin resistance in patients with INH-R pulmonary tuberculosis given different durations of rifampicin, ethambutol, and pyrazinamide (REZ); a fluoroquinolone plus 6 months or more of REZ; and streptomycin plus a core regimen of REZ.<h4>Methods</h4>Studies with regimens and outcomes known for individual patients with INH-R tuberculosis were eligible, irrespective of the number of patients if randomised trials, or with at least 20 participants if a cohort study. Studi"],"journal":["The Lancet. Respiratory medicine"],"pubmed_title":["Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis."],"pmcid":["PMC9017096"],"funding_grant_id":["001","CC999999"],"pubmed_authors":["Jacobson KR","Tabarsi P","Cegielski P","Yoshiyama T","Bastos M","Munang M","Trajman A","Goldberg S","Escalante P","Nguyen VN","Erkens C","Lee JH","Baghaei P","Skrahina A","Reves R","Cattamanchi A","Li PZ","Fregonese F","Ayakaka I","Menzies D","Griffith D","Maciel EL","Merle CSC","Ponnuraja C","Benedetti A","Arakaki-Sanchez D","Seung K","Schaaf HS","Jones-Lopez EC","Chien JY","Koh WJ","Garcia-Prats AJ","Ahuja SD","Narendran G","Bang D","Galliez RM","Ohkado A","Glynn JR","Bonnet M","Gillespie SH","Johnston JC","Soolingen DV","Romanowski K","Falzon D","Khan A","Trieu L","Dedicoat M","Wang JY","Park JS","Cox H","Banurekha VV","Nunn A","Akkerman OW","Kritski A","Viiklepp P","Gegia M","Lan ZY","Phillips PPJ"],"additional_accession":[]},"is_claimable":false,"name":"Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.","description":"<h4>Background</h4>Isoniazid-resistant, rifampicin-susceptible (INH-R) tuberculosis is the most common form of drug resistance, and is associated with failure, relapse, and acquired rifampicin resistance if treated with first-line anti-tuberculosis drugs. The aim of the study was to compare success, mortality, and acquired rifampicin resistance in patients with INH-R pulmonary tuberculosis given different durations of rifampicin, ethambutol, and pyrazinamide (REZ); a fluoroquinolone plus 6 months or more of REZ; and streptomycin plus a core regimen of REZ.<h4>Methods</h4>Studies with regimens and outcomes known for individual patients with INH-R tuberculosis were eligible, irrespective of the number of patients if randomised trials, or with at least 20 participants if a cohort study. Studi","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Apr","modification":"2026-06-03T10:17:48.74Z","creation":"2025-02-18T23:35:47.492Z"},"accession":"S-EPMC9017096","cross_references":{"pubmed":["29595509"],"doi":["10.1016/S2213-2600(18)30078-X","10.1016/s2213-2600(18)30078-x"]}}